Extracellular vesicles derived from amniotic fluid and their uses in wound healing
DE602020070045T2Active Publication Date: 2026-04-08MERAKRIS THERAPEUTICS LLC
0 Cites 0 Cited by
Patent Information
- Application Number
- DE602020070045
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-02-28
- Filing Date
- 2020-02-27
- Publication Date
- 2026-04-08
- Estimated Expiration
- 2040-02-27
AI Technical Summary
Technical Problem
The variability in the molecular composition of amniotic tissue and fluid poses challenges for standardizing and reproducing the efficacy of amniotic-derived products in therapeutic applications, particularly in wound healing, due to donor-to-donor variation and issues with collection and storage.
Method used
The use of purified amniotic fluid-derived extracellular vesicles (EVs) as a standardized therapeutic agent, which are isolated and formulated to enhance wound healing by delivering growth factors and cytokines.
Benefits of technology
Purified amniotic fluid-derived EVs provide a consistent and effective means to stimulate tissue repair and promote skin and connective tissue homeostasis, addressing the variability issues in amniotic fluid-derived therapies.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.